Please use this identifier to cite or link to this item: http://hdl.handle.net/11718/26169
Full metadata record
DC FieldValueLanguage
dc.contributor.advisorRai, Rajnish-
dc.contributor.authorIrshad Ansari, Mohammad-
dc.contributor.authorAnsari, Khalid-
dc.date.accessioned2023-03-24T08:37:53Z-
dc.date.available2023-03-24T08:37:53Z-
dc.date.issued2021-09-07-
dc.identifier.urihttp://hdl.handle.net/11718/26169-
dc.description.abstractWith the world on the onset of witnessing one of the longest pandemics leading to various responses from different countries like imposing lockdown, compulsion linked to use of mask and ban on international trade and exchange. But one thing that is common everywhere is that this pandemic showed how unprepared humans as a community are when faced with this type of situation, and losses can be substantial whether in terms of many deaths or massive contraction in the GDP. It is estimated that the Covid-19 cost approx. $19 trillion to the US only, and this cost at the worldwide level can be easily somewhere 10-15X of the US figures. All these points and monetary losses put a question mark on the existing practices followed by the pharmaceutical companies and the role of the regulators/government.en_US
dc.language.isoenen_US
dc.publisherIndian Institute of Management Ahmedabaden_US
dc.subjectStrategic patentingen_US
dc.subjectPharma companiesen_US
dc.subjectPandemicsen_US
dc.subjectStakeholdersen_US
dc.titleStrategic patenting by pharma companies during pandemics & its impact on various stakeholdersen_US
dc.typeStudent Projecten_US
Appears in Collections:Student Projects

Files in This Item:
File Description SizeFormat 
Strategic_patenting_by_pharma_companies_during_pandemics_&_its_impact_on_various_stakeholders.pdf
  Restricted Access
1.64 MBAdobe PDFView/Open Request a copy


Items in IIMA Institutional Repository are protected by copyright, with all rights reserved, unless otherwise indicated.